Switch theme
Sign up to access all valuation multiples
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing, and commercializing potentially transformative gene therapies for severe genetic diseases.
1992
248
LTM Revenue $146M
LTM EBITDA -$227M
$158M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
bluebird bio has a last 12-month revenue (LTM) of $146M and a last 12-month EBITDA of -$227M.
In the most recent fiscal year, bluebird bio achieved revenue of $83.8M and an EBITDA of -$157M.
bluebird bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See bluebird bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $146M | XXX | $83.8M | XXX | XXX | XXX |
| Gross Profit | $146M | XXX | -$5.6M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | -7% | XXX | XXX | XXX |
| EBITDA | -$227M | XXX | -$157M | XXX | XXX | XXX |
| EBITDA Margin | -155% | XXX | -187% | XXX | XXX | XXX |
| EBIT | -$230M | XXX | -$268M | XXX | XXX | XXX |
| EBIT Margin | -157% | XXX | -319% | XXX | XXX | XXX |
| Net Profit | -$215M | XXX | -$241M | XXX | XXX | XXX |
| Net Margin | -147% | XXX | -287% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $9.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, bluebird bio's stock price is $5.
bluebird bio has current market cap of $48.7M, and EV of $158M.
See bluebird bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $158M | $48.7M | XXX | XXX | XXX | XXX | $-20.52 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, bluebird bio has market cap of $48.7M and EV of $158M.
bluebird bio's trades at 1.9x EV/Revenue multiple, and -1.0x EV/EBITDA.
Equity research analysts estimate bluebird bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
bluebird bio has a P/E ratio of -0.2x.
See valuation multiples for bluebird bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $48.7M | XXX | $48.7M | XXX | XXX | XXX |
| EV (current) | $158M | XXX | $158M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | -0.7x | XXX | -1.0x | XXX | XXX | XXX |
| EV/EBIT | -0.7x | XXX | -0.6x | XXX | XXX | XXX |
| EV/Gross Profit | 1.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free Trialbluebird bio's last 12 month revenue growth is 116%
bluebird bio's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.1M for the same period.
bluebird bio's rule of 40 is -451% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
bluebird bio's rule of X is 135% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for bluebird bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 116% | XXX | 121% | XXX | XXX | XXX |
| EBITDA Margin | -155% | XXX | -187% | XXX | XXX | XXX |
| EBITDA Growth | -28% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -451% | XXX | -71% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 135% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 112% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 313% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
bluebird bio acquired XXX companies to date.
Last acquisition by bluebird bio was XXXXXXXX, XXXXX XXXXX XXXXXX . bluebird bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was bluebird bio founded? | bluebird bio was founded in 1992. |
| Where is bluebird bio headquartered? | bluebird bio is headquartered in United States of America. |
| How many employees does bluebird bio have? | As of today, bluebird bio has 248 employees. |
| Who is the CEO of bluebird bio? | bluebird bio's CEO is Mr. Andrew Obenshain. |
| Is bluebird bio publicy listed? | Yes, bluebird bio is a public company listed on NAS. |
| What is the stock symbol of bluebird bio? | bluebird bio trades under BLUE ticker. |
| When did bluebird bio go public? | bluebird bio went public in 2013. |
| Who are competitors of bluebird bio? | Similar companies to bluebird bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of bluebird bio? | bluebird bio's current market cap is $48.7M |
| What is the current revenue of bluebird bio? | bluebird bio's last 12 months revenue is $146M. |
| What is the current revenue growth of bluebird bio? | bluebird bio revenue growth (NTM/LTM) is 116%. |
| What is the current EV/Revenue multiple of bluebird bio? | Current revenue multiple of bluebird bio is 1.1x. |
| Is bluebird bio profitable? | Yes, bluebird bio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of bluebird bio? | bluebird bio's last 12 months EBITDA is -$227M. |
| What is bluebird bio's EBITDA margin? | bluebird bio's last 12 months EBITDA margin is -155%. |
| What is the current EV/EBITDA multiple of bluebird bio? | Current EBITDA multiple of bluebird bio is -0.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
